Information Provided By: 
Fly News Breaks for February 15, 2018
AMAG
Feb 15, 2018 | 11:13 EDT
Cowen analyst Ken Cacciatore says Amag Pharmaceuticals has had a nice start to 2018, with the Makena autoinjector approval "now part of the recovery." While encouraged by recent developments, the analyst remains focused on the Intrarosa launch and any potential generics of Makena. He sees a number a "similarly positioned inexpensive companies, but with a better collection of assets." As such, Cacciatore keeps a Market Perform rating on Amag. He dropped his price target for the shares to $20 from $22.
News For AMAG From the Last 2 Days
There are no results for your query AMAG
